Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...
Life Science Leader11h
How To Get Ready For The Talent Migration Between Pharma And Biotech
A looming patent cliff is driving Big Pharma reorganization. Executives making career moves must understand differences in ...
Fierce Pharma1d
Eyeing blockbuster sales, Harmony names Takeda veteran Zaeske chief commercial officer
Harmony Biosciences has named Adam Zaeske its next chief commercial officer, luring the Takeda veteran back from Europe to ...
PharmAla Contracts with Partner to Act as US Distributor
PharmAla’s agreement with its partner should provide for a streamlined warehoused, GMP-compliant supply of LaNeo™ MDMA for all current clients already contracted, and should provide exceptional ...
Fierce Pharma4d
Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlook
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...